NDA 020905 · Sanofi Aventis US
Arava
Leflunomide · Oral · Antirheumatic Agent
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jun 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1998
Sep 10, 1998
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
124
32 Phase 3, 20 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Leflunomide" as an intervention, any sponsor and status, largest first.
- An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core StudiesPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00720798 · 2,067 participants · Start Sep 2005 · Primary completion Apr 2013
Drug: Tocilizumab; Disease-modifying anti-rheumatic drugs and 2 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Mesa, Arizona · 295 sites in all
- A Clinical Study of a Natural Remedy for Rheumatoid Arthritis vs. Commonly Used Conventional MedicationsPivotal-lookingCompleted
University of MinnesotaAcademic, hospital or other
NCT01600521 · 1,748 participants · Start Nov 2004 · Primary completion Apr 2011
Drug: A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs · For: Rheumatoid Arthritis
Sites: Beijing, China; Taipa, China
- Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF TherapyPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT00124982 · 1,286 participants · Start Apr 2005 · Primary completion Aug 2009
Drug: Abatacept; Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) and 1 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Paradise Valley, Arizona · 148 sites in all
- A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)Pivotal-lookingTerminated
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT00476996 · 836 participants · Start May 15, 2007 · Primary completion Jan 21, 2010
Drug: Leflunomide; Methotrexate and 3 more · For: Rheumatoid Arthritis
Sites: Anniston, Alabama; Birmingham, Alabama; Huntsville, Alabama · 266 sites in all
- A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid ArthritisPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00531817 · 619 participants · Start Oct 2007 · Primary completion Jun 2009
Drug: Tocilizumab; Placebo and 1 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Montgomery, Alabama; Lake Havasu City, Arizona · 157 sites in all
- To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT01709578 · 546 participants · Start Oct 2012 · Primary completion Mar 2015
Drug: Sarilumab; placebo and 4 more · For: Rheumatoid Arthritis
Sites: Anniston, Alabama; Birmingham, Alabama; Phoenix, Arizona · 196 sites in all
- Disease-Modifying Antirheumatic Drugs Cycle Combination Therapy ResearchPivotal-lookingStatus unknown
Shanxi Medical UniversityAcademic, hospital or other
NCT01617590 · 500 participants (planned) · Start May 2012 · Primary completion Dec 2013
Drug: leflunomide; methotrexate · For: Rheumatoid Arthritis
Sites: Taiyuan, China
- Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) TreatmentPivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT02873936 · 449 participants · Start Jul 27, 2016 · Primary completion Mar 20, 2018
Drug: Filgotinib; Placebo to match filgotinib and 1 more · For: Rheumatoid Arthritis
Sites: Huntsville, Alabama; Gilbert, Arizona; Covina, California · 104 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Arava (Leflunomide)
2024 spending
$914K
Beneficiaries
93
381 claims
Per beneficiary
$9,830
$47.93 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $941,808 |
| 2021 | $852,155 |
| 2022 | $1,086,920 |
| 2023 | $1,045,335 |
| 2024 | $914,198 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A, Smolen JS, Ferreira RJO, et al. · Ann Rheum Dis 2024 · Systematic Review
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Gonzalez-Lorenzo M, Ridley B, Minozzi S, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Rheumatoid arthritis.
Walker-Bone K, Farrow S · BMJ Clin Evid 2007 · Systematic Review
- The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.
Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. · Ann Rheum Dis 2016 · Consensus Statement, Systematic Review
- Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Kerschbaumer A, Sepriano A, Bergstra SA, et al. · Ann Rheum Dis 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- What are the core recommendations for rheumatoid arthritis care? Systematic review of clinical practice guidelines.
Conley B, Bunzli S, Bullen J, et al. · Clin Rheumatol 2023 · Systematic Review
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.